医学
药物输送
类风湿性关节炎
药品
软骨
免疫抑制
抗风湿药物
药理学
免疫学
抗风湿药
纳米技术
解剖
材料科学
作者
Xin An,Jiapei Yang,Jing Chen,Jiaxuan Zhao,Chenwei Jiang,Ming Tang,Yabing Dong,Lin Li,Hui Li,Hui Li,Feihu Wang
标识
DOI:10.1016/j.addr.2024.115325
摘要
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by an inflammatory microenvironment and cartilage erosion within the joint cavity. Currently, antirheumatic agents yield significant outcomes in RA treatment However, their systemic administration is limited by inadequate drug retention in lesion areas and non-specific tissue distribution, reducing efficacy and increasing risks such as infection due to systemic immunosuppression. Development in local drug delivery technologies, such as nanostructure-based and scaffold-assisted delivery platforms, facilitate enhanced drug accumulation at the target site, controlled drug release, extended duration of the drug action, reduced both dosage and administration frequency, and ultimately improve therapeutic outcomes with minimized damage to healthy tissues. In this review, we introduced pathogenesis and clinically used therapeutic agents for RA, comprehensively summarized locally administered nanostructure-based and scaffold-assisted drug delivery systems, aiming at improving the therapeutic efficiency of RA by alleviating the inflammatory response, preventing bone erosion and promoting cartilage regeneration. In addition, the challenges and future prospects of local delivery for clinical translation in RA are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI